ETIDIOH - NEW

  Abstract This study aimed to investigate the prevalence of heart failure (HF) among adults aged ≥ 40 years using health checkup and medical claim data in Fukushima from 2015 to 2021 . Joinpoint regression and age-period-cohort analyses were conducted to estimate temporal trends. Age-standardized prevalence and hospital admission rates for HF were 37.0 and 7.4/1000 and 25.9 and 5.3/1000 for men and women, respectively. The prevalence was significantly higher in the coastal area and evacuation zone designated after the 2011 disaster compared to the prefecture overall. In men, the prevalence increased continuously, with an average annual percentage change (AAPC) ranging from 0.72% (evacuation zone) to 1.15% (mountainous area) (P < 0.05). In total residents, the AAPC was significant only in the mountainous areas (0.78%, P = 0.021). Age-period-cohort analysis showed a net drift of 2.50% (95% CI 1.88–3.13%) in men and 0.76% (95% CI − 0.17–1.70%) in women. Cohort rate ratios increase...

  Abstract   SARS-CoV-2 is a major global public health burden associated with significant morbidity, mortality, and complications , including respiratory, cardiovascular, neurological , and digestive disorders. COVID-19 may induce venous and arterial thromboembolic complications , including deep vein thrombosis , myocardial infarction and cerebral infarction . Simultaneous myocardial and cerebral infarction, termed cardio-cerebral infarction , is exceedingly rare. There is only limited case of concurrent cardio-cerebral infarction in patients with COVID-19 . Although there is no standard treatment for the condition, antiplatelet and anticoagulation agents should be used. We emphasize the catastrophic coexistence of concurrent cardio-cerebral infarction in a patient co-infected with SARS-CoV-2 and influenza A. We described a 75-year-old woman was admitted for SARS-CoV-2 and influenza A coinfection . She received anti-viral agent treatment for the virus infection. The patient p...

  Abstract While treatment with nirmatrelvir/ritonavir or molnupiravir is effective in lowering the rate of severe COVID-19 , the effectiveness of these antivirals in reducing the risk of cardiovascular outcomes, especially among the hospitalized population, remains largely unknown . In this study, we assessed the real-world effectiveness of nirmatrelvir/ritonavir and molnupiravir on short- and long-term cardiovascular complications of COVID-19 using a target trial emulation design. Two target trials of COVID-19 antivirals were emulated by using a territory-wide, population-based, retrospective cohort of hospitalized patients in Hong Kong . Nine cardiovascular outcomes were evaluated in both short-term (day 0–21) and long-term (day 22–365) post-SARS-CoV-2 infection. Compared with the control group , the use of nirmatrelvir/ritonavir was associated with a significantly lower one-year risk of cardiovascular mortality , composite cardiovascular complications, major adverse cardiac eve...

  Summary Background Influenza vaccination is widely recommended to prevent death and serious illness in vulnerable people , including those with heart failure . However, the randomised evidence to support this practice is limited and few people are vaccinated in many parts of the world. We aimed to determine whether influenza vaccination can improve the outcome of patients after an episode of acute heart failure requiring admission to hospital in China . Methods We undertook a pragmatic, multiregional, parallel-group, cluster (hospital)-randomised, controlled, superiority trial over three winter seasons in China. Participating hospitals were located in the counties of 12 provinces with the capability of establishing a point-of-care service to provide free influenza vaccination to a sufficient number of patients before their discharge, if allocated to the intervention group. No such service was used in hospitals allocated to usual care (control) but patients were informed of fee-fo...